U.S. market Open. Closes in 13 minutes

BXRX | Baudax Bio, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for BXRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is on medium level and Health is frighteningly weak.

Valuation (5%)

Company Industry
P/E Ratio (TTM) -0.21 -23.05
PEG Ratio (TTM) 0.00 15.47
P/S Ratio (TTM) 24.93 49.46
P/B Ratio (TTM) -0.15 18.87
P/FCF Ratio (TTM) -0.57 -3.27
Price to 5YR AVG Earnings Ratio 0.00 -3.55
Price to 5YR AVG FCF Ratio -0.17 -9.37

Profitability (50%)

Company Industry
ROA (TTM) -34.76% -5.14%
ROE (TTM) 54.54% 16.69%
Net Profit Margin (TTM) -2,194.48% -1,583.93%
ROIC 5YR AVG 166.76% 15.15%

Growth (60%)

4QTR AVG 3YR AVG 5YR AVG
EPS 58.43% 21.40% 41.76%
Revenue 35.01% N/A 27.31%
Net Income 50.18% -89.25% -78.23%
Cash Flow 8.88% -3.29% 4.38%

Health (7%)

Company Industry
Current Ratio (TTM) 0.07 6.13
Quick Ratio (TTM) 0.02 5.85
D/E Ratio (TTM) -0.79 -15.81
Interest Coverage (TTM) 1.44 -1.57
Piotroski F-Score 3 5
Altman Z-Score N/A 14.12
LTL to 5YR AVG FCF -0.03 0.17
Shares Outstanding Growth 5YR AVG 32,160.53% 123.44%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙